Rodrigo Juan P, Sánchez-Canteli Mario, Triantafyllou Asterios, de Bree Remco, Mäkitie Antti A, Franchi Alessandro, Hellquist Henrik, Saba Nabil F, Stenman Göran, Takes Robert P, Valero Cristina, Zidar Nina, Ferlito Alfio
Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Cancers (Basel). 2023 Jan 28;15(3):802. doi: 10.3390/cancers15030802.
Neutrophil-to-lymphocyte ratio (NLR) has been associated with survival in various cancers, including head and neck cancer. However, there is limited information on its role in oropharyngeal squamous cell carcinomas (OPSCC) according to HPV status. This prompted the present meta-analysis. Studies were selected when the prognostic value of NLR prior to treatment was evaluated in OPSCC patients, the cutoff value of NLR was available, and the prognostic value of NLR was evaluated by time-to-event survival analysis. A total of 14 out of 492 articles, including 7647 patients, were analyzed. The results showed a worse prognosis for the patients with a high NLR: The combined hazard ratios (HR) for overall survival (OS) in patients with an elevated NLR was 1.56 (95% confidence interval (CI) 1.21-2.02; = 0.0006), for disease-free survival was 1.52 (95% CI 1.34-1.73; < 0.00001), and for recurrence-free survival was 1.86 (95% CI 1.50-2.30; < 0.00001). This worse prognosis of high NLR was exclusive of HPV-positive patients: HR for OS in the HPV-positive subgroup was 4.05 (95% CI 1.90-8.62 ( = 0.0003), and in the HPV-negative subgroup 0.92 (95% CI 0.47-1.80; = 0.82). The prognosis of NLR was not influenced by treatment: The HR for OS for patients treated with radiotherapy/chemoradiotherapy (RT/CRT) was 1.48 (95% CI 1.09-2.01; = 0.01), and for patients treated with surgery (±RT/CRT) was 1.72 (95% CI 1.08-2.72; = 0.02). In conclusion, an elevated NLR relates to worse outcomes in patients with HPV-positive OPSCC.
中性粒细胞与淋巴细胞比值(NLR)已被证实与包括头颈癌在内的多种癌症的生存率相关。然而,关于其在根据人乳头瘤病毒(HPV)状态分类的口咽鳞状细胞癌(OPSCC)中的作用,相关信息有限。这促使了本次荟萃分析。当在OPSCC患者中评估治疗前NLR的预后价值、NLR的临界值可用且通过事件发生时间生存分析评估NLR的预后价值时,对研究进行筛选。在492篇文章中,共14篇被分析,涉及7647名患者。结果显示,NLR高的患者预后较差:NLR升高的患者总生存(OS)的合并风险比(HR)为1.56(95%置信区间(CI)1.21 - 2.02;P = 0.0006),无病生存的HR为1.52(95% CI 1.34 - 1.73;P <0.00001),无复发生存的HR为1.86(95% CI 1.50 - 2.30;P <0.00001)。NLR高导致的这种较差预后不包括HPV阳性患者:HPV阳性亚组中OS的HR为4.05(95% CI 1.90 - 8.62;P = 0.0003),HPV阴性亚组中为0.92(9% CI 0.47 - 1.80;P = = 0.82)。NLR的预后不受治疗影响:接受放疗/放化疗(RT/CRT)的患者OS的HR为1.48(95% CI 1.09 - 2.01;P = = 0.01),接受手术(±RT/CRT)的患者为1.72(95% CI 1.08 - 2.72;P = 0.02)。总之,NLR升高与HPV阳性的OPSCC患者的较差预后相关。